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minimal side effects / acceptable side effect profile, effective medica-
tion, and tolerability.
Conclusions
Most patients in Germany are treated with acute medications only,
although many experience headache frequencies indicating preven-
tion eligibility. Notably, patients with chronic headache frequency (15
+ HD) have low preventive treatment use and high combination OTC
and acute prescription use. Considerable impairment in work prod-
uctivity and daily activity was observed across all headache fre-
quency groups.
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Background: Cluster headache (CH) is a disabling primary headache
disorder characterized by episodic attacks of intense unilateral head-
ache with autonomic symptoms and/or restlessness or agitation. Pa-
tients with episodic CH (approximately 85.0% of CH patients) have
cluster periods typically lasting 2-12 weeks and differ diagnostically
from chronic CH patients based on duration of remissions. Increased
blood levels of calcitonin gene-related peptide (CGRP) have been as-
sociated with CH, making CGRP a potential therapeutic target. The
objective of this study was to assess the efficacy and safety of galca-
nezumab, a CGRP monoclonal antibody, in patients with episodic CH.
In this abstract, we report on baseline demographics and disease
characteristics of these patients.
Methods: This phase 3, randomized, double-blind, placebo-controlled
study enrolled patients aged 18-65 years who met International Clas-
sification of Headache Disorders, 3rd edition, beta version diagnostic
criteria for episodic CH and had a prior history of a cluster period
that lasted ≥6 weeks. During the prospective baseline, patients were
required to have a total of ≥4 attacks, with an attack frequency of at
least one attack every other day but ≤8 attacks/day. Certain concomi-
tant abortive (but not preventive) treatments were allowed. Eligible
patients were randomized to galcanezumab 300 mg or placebo ad-
ministered subcutaneously once monthly for 2 months. Analyses
were conducted on an intent-to-treat population.
Results: A total of 106 patients were randomized and treated with
galcanezumab 300 mg (N=49) or placebo (N=57). Overall, the patient
population was predominately male (83.0%) and white (84.9%), with
a mean age of 46.4 years and the majority from Europe (66.0%).
Mean duration of CH illness was 16.8 years. Lifetime suicidal ideation
and suicidal behavior before screening was reported by 13.2% and
0.9% of patients, respectively. Current tobacco and nicotine com-
bined use was reported by 53.8% of patients, while 26.4% reported
prior use. The most common pre-existing conditions were insomnia
(10.4%), gastroesophageal reflux disease (10.4%), and hypercholester-
olemia (7.6%). During the prospective baseline period, patients had
an average of 17.5 CH attacks per week. Average pain severity of the
CH attack was 2.5 on a 5-point scale (moderate to severe). The aver-
age weekly total of CH attack duration was 15.5 hours. The propor-
tion of patients using oxygen and/or subcutaneous sumatriptan
during the prospective baseline period was 45.3% and 56.6%,
respectively.
Conclusion: These data build upon the existing data to provide de-
scriptive characteristics of the episodic CH population.
Ethics approval
The study was approved by a central Ethics Review Board and regis-
tered on ClinTrials.gov (NCT02397473).
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Background: OnabotulinumtoxinA is an effective, tolerable and safe
preventive treatment for chronic migraine (CM). Other than a reduc-
tion in headache frequency or disability, in CM the withdrawal of
concomitant preventive medication indicates treatment effectiveness
and quality of life improvement.
Objective: To characterize the change in the use of oral preventive
medication after treatment with OnabotulinumtoxinA in patients
with migraine.
Methods: This is a multicentre study. We consecutively included pa-
tients with migraine (ICHD-3) that were on preventive treatment with
OnabotulinumtoxinA. We retrospectively collected demographic data,
diagnosis of migraine, frequency and intensity changes, number of
cycle and OnabotulinumtoxinA dose. In addition, we listed the initial
and current preventive treatment (number of drugs and group) and
the number and cycle of medications withdrawn. We performed a
univariate and logistic regression analysis.
Results: We included 542 patients: 87.6% women, mean age 47.6 ±
11.7 years. A 89.3% had chronic migraine and 10.8% had high fre-
quency episodic migraine. The mean reduction in frequency after
treatment was 13.4±8.2 headache days/month. At baseline, a 91.3%
took other preventives and during treatment with Onabotulinumtox-
inA a 58.6% withdrew at least one drug, 25.8% stopped completely
all oral preventive drugs. Factors associated with withdrawal were:
being male, having >50% response in frequency and intensity, the
number of infiltrations and a shorter chronification period until the
first OnabotulinumtoxinA administration (p <0.05). The multivariate
analysis showed that a better response in intensity (OR:1.8 [1.4-2.2],
p<0.001), a greater number of infiltrations (OR:1.1 [1.0-1.2], p<0.001)
and a shorter chronification period (OR:0.994 [0.992-0.997], p<0.001)
were predictors of withdrawal. The ROC curve, showed that 6 Onabo-
tulinumtoxinA cycles was the cut-off point that better predicted oral
preventive medication withdrawal (p <0.001).
Conclusions: Treatment with OnabotulinumtoxinA reduces the use of
other preventive medications for migraine. The highest probability of
withdrawal occurs after 6 cycles of treatment.
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